Association between intraepithelial T-cell infiltration (TIL CD3 + ) and patient survival Association between intraepithelial T-cell infiltration (TIL CD8 + ) and patient survival (only for high grade serous EOC, but not for endometrioïd or mucinous EOC), 2007. ,
Association between intraepithelial T-cell infiltration (TIL CD8 + ) and optimal debulking surgery Tomsova M Association between intraepithelial T-cell infiltration (TIL CD3 + ) and patient survival, Association between intraepithelial T-cell infiltration (TIL CD8 + ) and patient survival, 2008. ,
Association between intraepithelial T-cell infiltration (TIL CD3 + and CD8 + ) and patient survival Stumpf M et al. [29] 2009 Association between intraepithelial T-cell infiltration (TIL CD3 + and CD8 + ) and patient survival Leffers N, Association between intraepithelial T-cell infiltration (TIL CD8 + ) and patient survival, 2008. ,
Association between intraepithelial T-cell infiltration (TIL CD3 + and CD8 + ) and patient survival Adams SF et al. [32] 2009 Association between intraepithelial T-cell infiltration (TIL CD3 + and CD8 + ) and patient survival Kryczek I et al. [35] 2009 Association between intraepithelial T-cell infiltration (TIL CD4 + with IL-17 secretion) and patient survival Tumor immune evasion Curiel TJ et al, Inverse association between survival and intratumoral regulatory T cells (CD4 + CD25 + FoxP3 + ), 2004. ,
Inverse association between survival and intratumoral B7-H4 + macrophage or regulatory T cells, 2007. ,
PD-L1 expression by tumor predicts low, 2007. ,
ET B R) expression restricts T-cell infiltration and predicts poor survival Labidi-Galy SI, Inverse association between survival and intratumoral pDC (CD4 + , CD123 + , BDCA2 + ), 2008. ,
Cancer Statistics, 2009, Cancer statistics, pp.225-249, 2009. ,
DOI : 10.3322/caac.20006
Management of Platinum-Sensitive Recurrent Ovarian Cancer, Seminars in Oncology, vol.33, pp.12-16, 2006. ,
DOI : 10.1053/j.seminoncol.2006.03.012
Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel, JNCI Journal of the National Cancer Institute, vol.102, issue.20, pp.1547-1556, 2010. ,
DOI : 10.1093/jnci/djq362
Immunologic principles and immunotherapeutic approaches in ovarian cancer, Hematology/Oncology Clinics of North America, vol.17, issue.4, pp.1051-1073, 2003. ,
DOI : 10.1016/S0889-8588(03)00064-9
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes, Cell Cycle, vol.9, issue.2, pp.260-268, 2010. ,
DOI : 10.4161/cc.9.2.10430
Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery11This work was supported by DFG grants Si 208/5-1 and Si 208/5-4 to the clinical research group, ???Immunosuppression und Postoperative Sepsis.???, The American Journal of Surgery, vol.177, issue.1, pp.55-60, 1999. ,
DOI : 10.1016/S0002-9610(98)00299-2
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression, Journal of Cellular and Molecular Medicine, vol.178, issue.12, pp.2748-2759, 2010. ,
DOI : 10.1111/j.1582-4934.2009.00911.x
Recovery of CD8+ T-Cell Function During Systemic Chemotherapy in Advanced Ovarian Cancer, Cancer Research, vol.65, issue.15, pp.7000-7006, 2005. ,
DOI : 10.1158/0008-5472.CAN-04-3792
Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogene, Cellular Immunology, vol.151, issue.1, pp.225-234, 1993. ,
DOI : 10.1006/cimm.1993.1233
Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group, Journal of Clinical Oncology, vol.21, issue.2, pp.283-290, 2003. ,
DOI : 10.1200/JCO.2003.10.104
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group, Annals of Oncology, vol.15, issue.1, pp.104-112, 2004. ,
DOI : 10.1093/annonc/mdh021
Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides, Annals of Surgical Oncology, vol.38, issue.8, pp.743-750, 1998. ,
DOI : 10.1007/BF02303486
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM, Gynecologic Oncology, vol.107, issue.3, pp.563-571, 2007. ,
DOI : 10.1016/j.ygyno.2007.08.064
Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas, Cancer Research, vol.65, issue.6, pp.2162-2169, 2005. ,
DOI : 10.1158/0008-5472.CAN-04-3924
Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer, Journal of Clinical Oncology, vol.24, issue.5, pp.762-768, 2006. ,
DOI : 10.1200/JCO.2005.03.2813
Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125), Modern Pathology, vol.13, issue.10 ,
DOI : 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A
Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines, BMC Cancer, vol.56, issue.1, p.163, 2010. ,
DOI : 10.1034/j.1399-0039.2000.560210.x
Tumor vaccine for ovarian carcinoma targeting sperm protein 17 regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Cancer Nat Med, vol.94, issue.10, pp.2447-2453942, 2002. ,
Antigen-Presenting Cell (APC) Subsets in Ovarian Cancer, International Reviews of Immunology, vol.10, issue.2-3, pp.120-126, 2011. ,
DOI : 10.4049/jimmunol.0802501
Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer, Clinical Cancer Research, vol.14, issue.23, pp.7667-7673, 2008. ,
DOI : 10.1158/1078-0432.CCR-08-0479
Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer, British Journal of Cancer, vol.181, issue.5, pp.685-692, 2010. ,
DOI : 10.1056/NEJMoa020177
The Expression of the Regulatory T Cell-Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer, Clinical Cancer Research, vol.11, issue.23, pp.8326-8331, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-1244
NK- and B-Cell Infiltration Correlates With Worse Outcome in Metastatic Ovarian Carcinoma, American Journal of Clinical Pathology, vol.125, issue.3, pp.451-458, 2006. ,
DOI : 10.1309/15B66DQMFYYM78CJ
Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma, Cancer Research, vol.67, issue.18, pp.8900-8905, 2007. ,
DOI : 10.1158/0008-5472.CAN-07-1866
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy, Nature Medicine, vol.32, issue.1, pp.28-36, 2008. ,
DOI : 10.1182/blood-2004-05-1906
Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer, Cancer Research, vol.71, issue.16, pp.5423-5434, 2011. ,
DOI : 10.1158/0008-5472.CAN-11-0367
URL : https://hal.archives-ouvertes.fr/hal-00849783
Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of V??9V??2 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy, International Journal of Cancer, vol.37, issue.Suppl. 2, pp.449-462, 2011. ,
DOI : 10.1002/ijc.27353
The Concept of Immunological Surveillance, Prog Exp Tumor Res, vol.13, pp.1-27, 1970. ,
DOI : 10.1159/000386035
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, Science, vol.331, issue.6024, pp.1565-1570, 2011. ,
DOI : 10.1126/science.1203486
Human Ovarian Tumor Cells Escape ???? T Cell Recognition Partly by Down Regulating Surface Expression of MICA and Limiting Cell Cycle Related Molecules, PLoS ONE, vol.329, issue.182, p.23348, 2011. ,
DOI : 10.1371/journal.pone.0023348.s005
Self/non-self discrimination by human ???? T cells: simple solutions for a complex issue?, Immunological Reviews, vol.153, issue.1, pp.123-135, 2007. ,
DOI : 10.1182/blood-2004-01-0331
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells, Molecular Cancer, vol.9, issue.1, p.1611, 2010. ,
DOI : 10.1186/1476-4598-9-11
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes, Molecular Cancer, vol.9, issue.1, p.118, 2010. ,
DOI : 10.1186/1476-4598-9-118
Macrophage Migration Inhibitory Factor Contributes to the Immune Escape of Ovarian Cancer by Down-Regulating NKG2D, The Journal of Immunology, vol.180, issue.11, pp.7338-7348, 2008. ,
DOI : 10.4049/jimmunol.180.11.7338
T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer, Proceedings of the National Academy of Sciences, vol.107, issue.17, pp.7875-7880, 2010. ,
DOI : 10.1073/pnas.1003345107
Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells, Clinical Cancer Research, vol.11, issue.16, pp.6030-6039, 2005. ,
DOI : 10.1158/1078-0432.CCR-04-2671
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma, Gynecologic Oncology, vol.115, issue.2, pp.185-192, 2009. ,
DOI : 10.1016/j.ygyno.2009.07.015
Creating immune privilege: active local suppression that benefits friends, but protects foes, Nature Reviews Immunology, vol.176, issue.1, pp.74-80, 2008. ,
DOI : 10.1038/nri2233
Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance, Immunological Investigations, vol.8, issue.6-7, pp.765-797, 2012. ,
DOI : 10.1038/nrd870
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression, Seminars in Cancer Biology, vol.22, issue.4, pp.275-281, 2012. ,
DOI : 10.1016/j.semcancer.2012.01.011
Blockade of B7-H1 improves myeloid dendritic cell???mediated antitumor immunity, Nature Medicine, vol.9, issue.5, pp.562-567, 2003. ,
DOI : 10.1038/nm863
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma, The Journal of Experimental Medicine, vol.6, issue.4, pp.871-881, 2006. ,
DOI : 10.1016/S0022-1759(01)00359-3
CD80 in Immune Suppression by Mouse Ovarian Carcinoma-Associated Gr-1+CD11b+ Myeloid Cells, Cancer Research, vol.66, issue.13, pp.6807-6815, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-3755
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells, The Journal of Experimental Medicine, vol.63, issue.3, pp.495-506, 2012. ,
DOI : 10.1056/NEJMoa020177
ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells, Cancer Research, vol.72, issue.23, pp.6130-6141, 2012. ,
DOI : 10.1158/0008-5472.CAN-12-2409
Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells, Cancer Research, vol.72, issue.20, pp.5240-5249, 2012. ,
DOI : 10.1158/0008-5472.CAN-12-2271
Tumor Evasion of the Immune System by Converting CD4+CD25- T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-??, The Journal of Immunology, vol.178, issue.5, pp.2883-2892, 2007. ,
DOI : 10.4049/jimmunol.178.5.2883
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells, Blood, vol.109, pp.2871-2877, 2007. ,
DOI : 10.1182/blood-2006-07-036863
Suppression, subversion and escape: the role of regulatory T cells in cancer progression, Clinical & Experimental Immunology, vol.114, issue.1, pp.36-45, 2013. ,
DOI : 10.1111/j.1365-2249.2012.04657.x
Functional Diversity and Plasticity of Human Dendritic Cell Subsets, International Journal of Hematology, vol.31, issue.3, pp.188-196, 2005. ,
DOI : 10.1532/IJH97.05012
In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells, Cancer Research, vol.69, issue.18, pp.7329-7337, 2009. ,
DOI : 10.1158/0008-5472.CAN-09-0835
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells, Nature Medicine, vol.7, issue.12, pp.1339-1346, 2001. ,
DOI : 10.1038/nm1201-1339
B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells, The Journal of Experimental Medicine, vol.11, issue.7, pp.839-846, 2001. ,
DOI : 10.1007/s003359900508
Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer, The Journal of Immunology, vol.186, issue.12, pp.6905-6913, 2011. ,
DOI : 10.4049/jimmunol.1100274
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, vol.8, pp.793-800, 2002. ,
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells, Proceedings of the National Academy of Sciences, vol.105, issue.27, pp.9331-9336, 2008. ,
DOI : 10.1073/pnas.0710441105
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes, Journal of Clinical Investigation, vol.114, issue.2, pp.280-290, 2004. ,
DOI : 10.1172/JCI200421583
The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function, Blood, vol.108, issue.13, pp.4118-4125, 2006. ,
DOI : 10.1182/blood-2006-03-006700
Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma, Ai Zheng, vol.28, pp.323-327, 2009. ,
Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression, Molecular Immunology, vol.46, issue.2, pp.258-268, 2008. ,
DOI : 10.1016/j.molimm.2008.08.266
PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment, Cancer Research, vol.71, issue.24, pp.7463-7470, 2011. ,
DOI : 10.1158/0008-5472.CAN-11-2449
TCR ?? Down-Regulation under Chronic Inflammation Is Mediated by Myeloid Suppressor Cells Differentially Distributed between Various Lymphatic Organs, The Journal of Immunology, vol.177, issue.7, pp.4763-4772, 2006. ,
DOI : 10.4049/jimmunol.177.7.4763
Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism, The Journal of Immunology, vol.168, issue.2, pp.689-695, 2002. ,
DOI : 10.4049/jimmunol.168.2.689
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer, Nature Medicine, vol.166, issue.7, pp.828-835, 2007. ,
DOI : 10.1038/nm1609
Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host, Cancer Research, vol.66, issue.2, pp.1123-1131, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-1299
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells, The Journal of Experimental Medicine, vol.57, issue.10, pp.1949-1962, 2011. ,
DOI : 10.1158/0008-5472.CAN-07-5324
ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-??-activated vascular endothelium under flow, Blood, vol.106, issue.2, pp.584-592, 2005. ,
DOI : 10.1182/blood-2004-12-4942
Soluble HLA-G molecules are increased in lymphoproliferative disorders, Human Immunology, vol.64, issue.11, pp.1093-1101, 2003. ,
DOI : 10.1016/j.humimm.2003.08.345
Peritoneal inflammation -A microenvironment for Epithelial Ovarian Cancer (EOC), Journal of Translational Medicine, vol.2, issue.1, p.23, 2004. ,
DOI : 10.1186/1479-5876-2-23
The impact of T-cell immunity on ovarian cancer outcomes, Immunological Reviews, vol.16, issue.1, pp.101-116, 2008. ,
DOI : 10.1158/0008-5472.CAN-07-0565
Human leukocyte antigen-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma, International Journal of Cancer, vol.11, issue.6, pp.1382-1390, 2011. ,
DOI : 10.1002/ijc.25807
Regulation of Invasion of Epithelial Ovarian Cancer by Transforming Growth Factor-??, Gynecologic Oncology, vol.80, issue.2, pp.245-253, 2001. ,
DOI : 10.1006/gyno.2000.6042
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients, Annals of Oncology, vol.13, issue.8, pp.1205-1211, 2002. ,
DOI : 10.1093/annonc/mdf207
PGE2 inhibits natural killer and ???? T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling, Biochemical Pharmacology, vol.80, issue.6, pp.838-845, 2010. ,
DOI : 10.1016/j.bcp.2010.05.002
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses, Molecular Cancer Therapeutics, vol.5, issue.3, pp.755-766, 2006. ,
DOI : 10.1158/1535-7163.MCT-05-0334
Indoleamine 2,3-Dioxygenase and Dendritic Cell Tolerogenicity, Immunological Investigations, vol.25, issue.2, pp.738-764, 2012. ,
DOI : 10.1111/j.1600-6143.2011.03624.x
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer, Cancer Research, vol.69, issue.13, pp.5498-5504, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-2106
3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion, Int J Oncol, vol.2, issue.38, pp.113-120, 2011. ,
GCN2 Kinase in T Cells Mediates Proliferative Arrest and Anergy Induction in Response to Indoleamine 2,3-Dioxygenase, Immunity, vol.22, issue.5, pp.633-642, 2005. ,
DOI : 10.1016/j.immuni.2005.03.013
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells ,
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion, Cancer Research, vol.72, issue.21, pp.5435-5440, 2011. ,
DOI : 10.1158/0008-5472.CAN-12-0569
Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study, Journal of Clinical Oncology, vol.26, issue.1, pp.83-89, 2008. ,
DOI : 10.1200/JCO.2007.13.1953
A Critique of Surgical Cytoreduction in Advanced Ovarian Cancer, Gynecologic Oncology, vol.78, issue.3, pp.269-274, 2000. ,
DOI : 10.1006/gyno.2000.5926
Distinct mechanisms of immunosuppression as a consequence of major surgery, Infect Immun, vol.65, pp.2283-2291, 1997. ,
Suppressing the suppressor: Role of immunosuppressive regulatory T cells in cancer surgery, Surgery, vol.145, issue.4, pp.345-350, 2009. ,
DOI : 10.1016/j.surg.2008.12.013
Immune parameters affecting the efficacy of chemotherapeutic regimens, Nature Reviews Clinical Oncology, vol.23, issue.3, pp.151-160, 2011. ,
DOI : 10.1038/nrclinonc.2010.223
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy, pp.491-503, 2011. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00576679
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice, Journal of Clinical Investigation, vol.120, issue.4, pp.1111-1124, 2010. ,
DOI : 10.1172/JCI40269DS1
Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment, Clinical Cancer Research, vol.10, issue.10, pp.3401-3409, 2004. ,
DOI : 10.1158/1078-0432.CCR-1016-03
The anticancer immune response: indispensable for therapeutic success?, Journal of Clinical Investigation, vol.118, issue.6, pp.1991-2001, 2008. ,
DOI : 10.1172/JCI35180
Immunogenic cancer cell death: a key-lock paradigm, Current Opinion in Immunology, vol.20, issue.5, pp.504-511, 2008. ,
DOI : 10.1016/j.coi.2008.05.007
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, The Journal of Experimental Medicine, vol.157, issue.12, pp.1691-1701, 2005. ,
DOI : 10.1073/pnas.93.18.9730
Immunotherapy for Ovarian Cancer: What's Next?, Journal of Clinical Oncology, vol.29, issue.7, pp.925-933, 2011. ,
DOI : 10.1200/JCO.2009.27.2369
Immunity and immune suppression in human ovarian cancer, Immunotherapy, vol.3, issue.4, pp.539-556, 2011. ,
DOI : 10.2217/imt.11.20
Antigen-specific active immunotherapy for ovarian cancer, Cochrane Database Syst Rev, vol.2010, issue.1, p.20091627 ,
Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer, Gynecologic Oncology, vol.113, issue.3, pp.384-390, 2009. ,
DOI : 10.1016/j.ygyno.2009.01.008
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer, Journal of Clinical Oncology, vol.27, issue.3, pp.418-425, 2009. ,
DOI : 10.1200/JCO.2008.17.8400
Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125: Immunological Response and Survival (Phase Ib/II), Clinical Cancer Research, vol.10, issue.5, pp.1580-1587, 2004. ,
DOI : 10.1158/1078-0432.CCR-03-0056
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR, Annals of Oncology, vol.17, issue.10 ,
DOI : 10.1093/annonc/mdl357
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer, Journal of Clinical Oncology, vol.28, issue.7, pp.1215-1223, 2010. ,
DOI : 10.1200/JCO.2009.22.3354
Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor ??, in Epithelial Ovarian Cancer: a Phase I Study, Clinical Cancer Research, vol.16, issue.21, pp.5288-5295, 2010. ,
DOI : 10.1158/1078-0432.CCR-10-0700
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial, International Journal of Cancer, vol.84, issue.Suppl, pp.2209-2221, 2010. ,
DOI : 10.1002/ijc.25423
Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity, Clin Cancer Res, vol.5, pp.953-961, 1999. ,
Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission, Clinical Cancer Research, vol.14, issue.9, pp.2740-2748, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-4619
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial, International Journal of Cancer, vol.14, issue.9, pp.2104-2113, 2009. ,
DOI : 10.1002/ijc.24597
Generation of T-cell immunity to the HER-2/neu protein after active immunization with ,
A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer, Journal of Immunotherapy, vol.31, issue.4, pp.420-430, 2008. ,
DOI : 10.1097/CJI.0b013e31816dad10
Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma, Clinical Cancer Research, vol.14, issue.10, pp.3060-3069, 2008. ,
DOI : 10.1158/1078-0432.CCR-08-0126
Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-?? for relapsed metastatic ovarian cancer, The Lancet Oncology, vol.8, issue.5, pp.451-454, 2007. ,
DOI : 10.1016/S1470-2045(07)70142-0
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells, Blood, vol.96, pp.3102-3108, 2000. ,
Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial, Cancer Immunology, Immunotherapy, vol.51, issue.1, pp.45-52, 2002. ,
DOI : 10.1007/s00262-001-0255-1
INDUCTION OF T CELL RESPONSES AGAINST AUTOLOGOUS OVARIAN TUMORS WITH WHOLE TUMOR CELL LYSATE-PULSED DENDRITIC CELLS, Immunological Investigations, vol.24, issue.24, pp.33-45, 2001. ,
DOI : 10.1081/IMM-100103689
Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer, Cancer Res, vol.51, pp.1934-1939, 1991. ,
Intraperitoneal Adoptive Immunotherapy of Ovarian Carcinoma with Tumor-Infiltrating Lymphocytes and Low-Dose Recombinant Interleukin-2, Journal of Immunotherapy, vol.16, issue.3 ,
DOI : 10.1097/00002371-199410000-00004
Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes, Clin Cancer Res, vol.1, pp.501-507, 1995. ,
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer, Clinical Cancer Research, vol.12, issue.20, pp.6106-6115, 2006. ,
DOI : 10.1158/1078-0432.CCR-06-1183
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival, Clinical Immunology, vol.133, issue.3, pp.333-352, 2009. ,
DOI : 10.1016/j.clim.2009.08.007
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions, The Journal of Gene Medicine, vol.365, issue.6, pp.405-415, 2012. ,
DOI : 10.1002/jgm.2604
The Basic Principles of Chimeric Antigen Receptor Design, Cancer Discovery, vol.3, issue.4, pp.388-398, 2013. ,
DOI : 10.1158/2159-8290.CD-12-0548
Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide, Cancer Res, vol.46, pp.2572-2577, 1986. ,
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients, Cancer Immunology, Immunotherapy, vol.95, issue.5, pp.641-648, 2007. ,
DOI : 10.1007/s00262-006-0225-8
Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma, Journal of Immunotherapy, vol.28, issue.6, pp.582-592, 2005. ,
DOI : 10.1097/01.cji.0000175468.19742.10
CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients, Science Translational Medicine, vol.4, issue.134, pp.25134-162, 2012. ,
DOI : 10.1126/scitranslmed.3003330
Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential, American Journal of Reproductive Immunology, vol.168, issue.6, pp.369-377, 2005. ,
DOI : 10.1038/ni904
Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses, The Journal of Experimental Medicine, vol.60, issue.6, pp.823-832, 2001. ,
DOI : 10.1084/jem.190.5.705
Th17 cells in cancer: help or hindrance? Carcinogenesis, pp.643-649, 2011. ,
Human Th17 cells in patients with cancer, OncoImmunology, vol.1, issue.8, pp.1438-1439, 2012. ,
DOI : 10.1038/ni1467
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity, Immunity, vol.31, issue.5, pp.787-798, 2009. ,
DOI : 10.1016/j.immuni.2009.09.014
The tumor-promoting actions of TNF-?? involve TNFR1 and IL-17 in ovarian cancer in mice and humans, Journal of Clinical Investigation, vol.119, issue.10, pp.3011-3023, 2009. ,
DOI : 10.1172/JCI39065DS1
URL : https://hal.archives-ouvertes.fr/hal-00499385
Chemokine Receptors as Targets for Cancer Therapy, Current Pharmaceutical Design, vol.15, issue.7, pp.742-757, 2009. ,
DOI : 10.2174/138161209787582165
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens, Blood, vol.118, issue.18, pp.4853-4862, 2011. ,
DOI : 10.1182/blood-2011-01-329656
URL : https://hal.archives-ouvertes.fr/pasteur-00711130
Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models, Clinical & Experimental Metastasis, vol.117, issue.4, pp.585-601, 2012. ,
DOI : 10.1007/s10585-012-9473-5
Myeloid-Derived Suppressor Cells Interact with Tumors in Terms of Myelopoiesis, Tumorigenesis and Immunosuppression: Thick as Thieves, Journal of Cancer, vol.4, issue.1, pp.3-11, 2013. ,
DOI : 10.7150/jca.5047
All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients, Cancer Research, vol.66, issue.18, pp.9299-9307, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-1690
ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents, Current Medicinal Chemistry, vol.19, issue.12, pp.1792-1803 ,
DOI : 10.2174/092986712800099785
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination, Clinical Cancer Research, vol.19, issue.5, pp.997-1008, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-2214
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti???CTLA-4 antibodies, The Journal of Experimental Medicine, vol.59, issue.8, pp.1717-1725, 2009. ,
DOI : 10.1126/science.1160062
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients, Proceedings of the National Academy of Sciences, vol.105, issue.8, pp.3005-3010, 2008. ,
DOI : 10.1073/pnas.0712237105
PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction, Clinical Cancer Research, vol.19, issue.6, pp.1363-1374, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-2199
Sznol M: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, vol.2012, issue.26, pp.3662443-245410, 1056. ,
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma, Clinical Cancer Research, vol.15, issue.20, pp.6341-6347, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1652
Safety and Activity of Anti???PD-L1 Antibody in Patients with Advanced Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2455-2465, 2012. ,
DOI : 10.1056/NEJMoa1200694
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy, Expert Opinion on Biological Therapy, vol.26, issue.4, pp.847-861 ,
DOI : 10.1056/NEJMe1205943
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma, Blood, vol.120, issue.22, pp.4324-4333, 2012. ,
DOI : 10.1182/blood-2012-06-438028
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission, Blood, vol.120, issue.22, pp.4317-4323, 2012. ,
DOI : 10.1182/blood-2012-06-437558
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity, Blood, vol.115, issue.17, pp.3520-3530, 2010. ,
DOI : 10.1182/blood-2009-09-246124
Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells, Cancer Research, vol.67, issue.9, pp.4507-4513, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-4174
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function, BMC Cancer, vol.18, issue.1, p.464, 2010. ,
DOI : 10.1158/1055-9965.EPI-08-0705
Celecoxib for the Prevention of Colorectal Adenomatous Polyps, New England Journal of Medicine, vol.355, issue.9, pp.885-895, 2006. ,
DOI : 10.1056/NEJMoa061652
Tumour macrophages as potential targets of bisphosphonates, Journal of Translational Medicine, vol.9, issue.1, p.177, 2011. ,
DOI : 10.1023/A:1013026313647
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma, British Journal of Cancer, vol.91, issue.5, pp.629-641, 2010. ,
DOI : 10.1038/sj.bjc.6603240